News

Pfizer Earnings Preview: What to Expect
Pfizer is expected to announce its second-quarter results next month, and analysts predict a single-digit drop in the company ...
Adrenal Crisis Market Analysis and Forecast Report 2025-2035 with Competitive Benchmarking of Eton Pharmaceuticals, Antares Pharma, and Pfizer
The global adrenal crisis market is witnessing significant growth driven by increasing adrenal insufficiency recognition and rising adrenal crisis incidents. The expanding global prevalence of ...
Nurix Therapeutics Could Disrupt BTK Therapy And Reward Investors
Nurix Therapeutics shows strong BTK degrader data and key pharma ties, with risks but solid long-term potential. Find out why ...
The Manila Times3h
Ascentage Pharma Announces Proposed Top-Up Placement
Ascentage Pharma Group International Inc. (NASDAQ: AAPG; HKEX: 6855) ('Ascentage” or the 'Company”), a global ...
Despite Revenue Jump, Novavax Appears Immune To Long-Term Growth
Novavax's growth relies on Sanofi royalties and COVID/flu vaccines, lacking innovation and clear catalysts. Click here to ...
Glenmark arm inks $700 million licensing deal with US-based AbbVie
Glenmark's arm IGI Therapeutics signs a $700 million licensing deal with AbbVie for its cancer drug ISB 2001, with potential ...
Harvard scrambles for corporate funding as Trump administration slashes billions in research grants
After losing most of its federal research budget, Harvard’s public health school—and other top universities—are turning to tech and pharma firms to fill the gap.
Global Clinical Trial Support Services Market Is Predicted To Cross USD 43 Billion By 2032 Delveinsight
The clinical trial support services market is experiencing significant growth, driven by the increasing incidence of chronic illnesses such as cancer ...
The Manila Times4d
Rakovina Therapeutics Highlights Strength of Scientific Advisory Board Driving Innovation in AI-Enabled Oncology Drug Development
Rakovina Therapeutics Inc. ('Rakovina” or the 'Company”) (TSX-V: RKV) (FSE: 7JO0), a biopharmaceutical company advancing next ...
Regenerative Medicine Market To Reach $45.66 Billion By 2032, Growing At A CAGR Of 22.0% From 2025, Says Meticulous Research®
Market Growth Driven by Increasing Drug Approvals, Advanced Technologies, Rising Chronic Disease Incidence, and Expanding Therapeutic Applica ...
2 Beaten-Down Stocks That Haven't Hit Rock Bottom Yet
Buying shares of beaten-down companies only makes sense if there are good reasons to expect them to bounce back. If that's not the case, stocks that may look cheap and attractive aren't actually so.